A brilliant, like-minded cardiologist recently shared with me “A Reappraisal of the Lipid Hypothesis” by Dr. Robert DuBroff, published in The American Journal of Medicine. It should be required reading for every physician who has ever written “continue statin” without a second thought.
DuBroff’s analysis reviewed 29 randomized controlled trials of cholesterol-lowering therapy conducted after modern trial regulations were adopted. The results were quietly devastating:
- Only two of 29 trials showed a mortality benefit.
- Nearly two-thirds showed no cardiovascular benefit at all.
And yet, the “LDL-C hypothesis” continues to dominate our guidelines, our CME, and our prescribing habits.
He calls out what many of us have privately felt that our field is marinated in confirmation bias and conflict of interest. The same “experts” shaping guidelines often have financial ties to the companies whose drugs the guidelines promote. Even worse, we selectively cite the studies that confirm our worldview while ignoring those that contradict it. Remember how the AIM-HIGH and HPS2-THRIVE trials ended niacin’s career overnight? Or how ILLUMINATE and REVEAL showed that sky-high HDL doesn’t translate to fewer events? Yet LDL remains sacred, despite decades of mixed results.
Meanwhile, real-world consequences mount:
- A generation of patients eats “low-cholesterol” foods that are actually high in refined carbs.
- Millions of healthy adults take lifelong statins for a calculated risk score, not actual disease.
- An epidemic of statin-associated diabetes is treated as collateral damage.
As DuBroff concludes, LDL is not the disease. It’s one biomarker in a complex, multifactorial process. Our LDL-centric model may have distracted us from deeper causes, such as inflammation, infection, and metabolic dysfunction, and kept us treating numbers instead of patients.
It’s time for a new humility in cardiology. A willingness to admit what the data actually say: that our reigning hypothesis explains less and less, even as our marketing grows louder. We owe it to our patients to re-examine what we think we know.
Larry Kaskel is an internist and “lipidologist in recovery” who has been practicing medicine for more than thirty-five years. He operates a concierge practice in the Chicago area and serves on the teaching faculty at the Northwestern University Feinberg School of Medicine. In addition, he is affiliated with Northwestern Lake Forest Hospital.
Before podcasts entered mainstream culture, Dr. Kaskel hosted Lipid Luminations on ReachMD, where he produced a library of more than four hundred programs featuring leading voices in cardiology, lipidology, and preventive medicine.
He is the author of Dr. Kaskel’s Living in Wellness, Volume One: Let Food Be Thy Medicine, works that combine evidence-based medical practice with accessible strategies for improving healthspan. His current projects focus on reevaluating the cholesterol hypothesis and investigating the infectious origins of atherosclerosis. More information is available at larrykaskel.com.
